Targeting the CCL2 axis with genetic ablation or pharmacological inhibition reduced the number of monocytes/macrophages in the pancreas and ameliorated the severity of CER-AP, ARG-AP, and NaTC-AP models (84–86). The gene discussed is CCL2; the disease is alkaline phosphatase measurement.